[ad_1]
The new single-dose vaccine is highly effective in preventing acute COVID-19 infection, including newer strains, the Food and Drug Administration (FDA) said before approving the vaccine developed by Johnson & Johnson.
“This is good news for all Americans and an encouraging boost in our efforts to end this crisis,” said US President Joe Biden.
However, he urged Americans to remain vigilant and adhere to restrictions imposed by the virus, such as social distancing requirements, and warned that new strains of the virus remain a threat.
“But we cannot relax now or think that victory is inevitable,” he said.
The vaccine developed by Johnson & Johnson is already the third COVID-19 vaccine certified for distribution in the United States.
It is seen as a crucial move to further accelerate the vaccination campaign in the United States, where the coronavirus infection has claimed more than 500,000 lives. human lives.
In large clinical trials, the effectiveness of the Johnson & Johnson vaccine in preventing severe COVID-19 was 85.9%. In the United States, 81.7 percent. In South Africa and 87.6 percent. In Brazil.
In all the mentioned regions, 39,321 thousand people participated in the research. in humans and the overall efficacy of the vaccine in preventing a severe form of infection was 85.4 percent, but, including milder forms of the disease, it was less than 66.1 percent.
However, it is important to note that the analysis of different demographic groups did not reveal significant differences in efficacy in terms of age, race or people with comorbidities.
[ad_2]
